Eli Lilly, Novo Nordisk prepare to face off in the next obesity drug battleground

In this articleLLYNOVO.B-DKwatch nowEli Lilly and Novo Nordisk are preparing to take their rivalry to the next frontier of weight-loss medications: pills.Both companies expect to launch oral obesity drugs in the U.S. next year, once regulators approve them. Daily pills could introduce more people to GLP-1s, the class of medicine that's best known for weekly shots.But after Lilly's pill produced less weight loss than analysts had expected in a recent late-stage trial, it raised new questions about how widely ...